摘要
在过去的20年里,我们对脱髓鞘性视神经炎(ON)的认识取得了显著进步。随着血清学检测技术的发展,近年来我们发现了一种特殊的抗体——髓鞘少突胶质细胞糖蛋白(MOG)抗体,它与脱髓鞘性ON的特定亚型有关。虽然MOG抗体相关疾病(MOGAD)最初被认为是视神经脊髓炎谱系疾病(NMOSD)的一部分,但越来越多的研究证据表明,我们应该将其视为一个独立的疾病实体。将MOGAD与水通道蛋白-4(AQP4)抗体阳性的NMOSD区分开来是非常重要的,因为它们具有不同的病程和预后,需要制定差异化的诊疗方案。为了提高MOG-ON诊疗水平并使这类患者获益更多,我们需要深入理解其临床表现和治疗进展,这将有助于为更多的神经眼科疾病患者提供更好的医疗服务。
Over the past two decades,significant advancements have been made in our understanding of optic neuritis(ON)characterized by demyelination.With the progression of serological testing technologies,a unique antibody associated with a specific subtype of demyelinating neuropathy was discovered in recent years—myelin oligodendrocyte glycoprotein(MOG)antibody.Although MOG antibody-associated disorders(MOGAD)were initially considered to be part of the spectrum of neuromyelitis optica spectrum disorders(NMOSD),accumulating research evidence suggests that it should be regarded as a distinct disease entity.It is crucial to differentiate MOGAD from aquaporin-4(AQP4)antibody-positive NMOSD because they have different clinical courses and prognoses,necessitating tailored diagnostic and treatment approaches.To enhance the level of diagnosis and treatment and enable greater benefits for these patients,there is a need for an in-depth comprehension of the clinical presentations and therapeutic advancements in MOG-ON.This will contribute to providing improved medical care for a broader range of neuro-ophthalmic patients.
作者
宋宏鲁
魏世辉
SONG Honglu;WEI Shihui(Senior Department of Ophthalmology,Chinese PLA General Hospital,Beijing 100853,China;Department of Ophthalmology,the 980th Hospital of the PLA Joint Logistics Support Force,Shijiazhuang 050082,China)
出处
《中国眼耳鼻喉科杂志》
2024年第5期337-342,共6页
Chinese Journal of Ophthalmology and Otorhinolaryngology
基金
国家重点研发计划项目(2018YFE0113900)
联勤保障部队第九八〇医院孵育计划项目(2024FYQNXM02)
河北省自然科学基金资助项目(H2024505013)。
关键词
髓鞘少突胶质细胞糖蛋白抗体
视神经炎
临床表现
治疗措施
Myelin oligodendrocyte glycoprotein antibody
Optic neuritis
Clinical presentations
Treatment measures
